Is Infliximab Appropriate for Stricturing-Type Crohn's Disease?

109 64
´╗┐Is Infliximab Appropriate for Stricturing-Type Crohn's Disease?


Is the anti-TNF agent infliximab effective in treatment of patients with stricturing-type Crohn's disease? What is the best approach to these patients?

Bret A. Lashner, MD
Professor of Medicine, Cleveland Clinic, Cleveland, Ohio

Infliximab plus the other antitumor necrosis factor (anti-TNF) agents, adalimumab and certolizumab, are effective in patients with Crohn's disease who have inflammatory-type disease. By the time intestinal strictures have developed, anti-TNF agents are no longer effective. Some evidence indicates that early Crohn's disease begins as inflammatory-type disease, and over time stricturing complications develop.

Evidence has also suggested that prescribing anti-TNF agents early in the course of disease is associated with a better response and a lower risk of developing complicated disease than starting anti-TNF treatment after strictures have developed. That said, some strictures have an inflammatory component and may respond to anti-TNF agents. These patients with strictures should be evaluated with computed tomographic (CT) enterography, small bowel follow-through, or ileocolonoscopy to document inflammatory-type lesions prior to instituting anti-TNF agents.

Therefore, in a patient with Crohn's disease with an intestinal stricture, prior to starting therapy with an anti-TNF agent, such as infliximab, I would suggest that the patient be monitored and only receive an anti-TNF agent if inflammatory-type disease is documented. Patients with stricturing disease who do not have an inflammatory component to their stricture should have surgical therapy.

Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.
You can unsubscribe at any time

Leave A Reply

Your email address will not be published.